Actively Recruiting
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2025-02-19
100
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of HRS-5041 in phase II study.
CONDITIONS
Official Title
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to provide written informed consent
- Age between 18 and 80 years old
- Eastern Tumor Cooperative Group (ECOG) physical status score of 0 to 1
- Predicted survival of at least 12 weeks
- Confirmed adenocarcinoma of the prostate by histology or cytology
- Progressed after taxane chemotherapy and at least one prior secondary hormonal therapy
You will not qualify if you...
- Prior treatment with an androgen receptor degrader
- Planning to receive any other antitumor therapy during the trial
- Use of other investigational drugs or treatments not on the market within 4 weeks before starting the study
- Known brain metastases
- Significant medical conditions such as uncontrolled infection, abnormal lab results, or psychiatric illness
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Jiaotong University School of Medicine, Renji Hospital
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
S
Suyu Fan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here